TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16557483
Drug: SJW herb
Normalized name: Purslane Herb
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SJW herb extract (LI‐160) 300 mg once daily
Study: 16557483
Drug: SJW herb
Normalized name: Purslane Herb
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SJW herb extract (LI‐160) 300 mg twice daily
Study: 14535628
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg/day) for 2 months
Study: 10735496
Drug: Interferon-gamma (IFN-gamma)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-gamma (IFN-gamma) 0.1 mg subcutaneously on days 1, 3, 5, 15, 17, and 19 of each 28-day cycle along with 100 mg/m(2) cisplatin and 600 mg/m(2) cyclophosphamide
Study: 10735496
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m(2) and cyclophosphamide 600 mg/m(2)
Study: 8723395
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (class effect)
Study: 8723395
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (various trials)
Study: 1414156
Drug: Danazol 150
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 150 mg/day for patients under 15 years and 300 mg/day for older patients
Study: 3908619
Drug: Polyadenylic-polyuridylic acid
Normalized name: polyacrylic acid (450000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyadenylic-polyuridylic acid (poly(A).poly(U)) as adjuvant treatment
Study: 27832366
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein drink (PRO 23.9 ± 3.6 g protein)
Study: 27832366
Drug: Dextrose drink
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose drink (CHO 26.5 ± 3.8 g carbohydrate)
Study: 22289570
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein isolate (20 g)
Study: 22289570
Drug: Micellar casein
Normalized name: Douxo Micellar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micellar casein (20 g)
Study: 18049943
Drug: Soy phytoestrogens
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy phytoestrogens 55 mg
Study: 16255136
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy for gastric cancer
Study: 16255136
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy for gastric cancer
Study: 12145148
Drug: Fish oils
Normalized name: fish oils
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oils (4 g/day)
Study: 12145148
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with atorvastatin and fish oils
Study: 10103335
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of Ritalin
Study: 10103335
Drug: 17.5 mg
Normalized name: acitretin 17.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17.5 mg of Ritalin
Study: 10103335
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg of Adderall
Study: 10103335
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg of Adderall
Study: 8852543
Drug: Lacidipine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (4 mg once daily)
Study: 6773725
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin (1.0 U/kg/h)
Study: 6773725
Drug: Low-dose insulin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose insulin (0.1 U/kg/h)
Study: 31696371
Drug: Daily-use product
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily-use product
Study: 28094033
Drug: saline+10μg/ml‐1 vancomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline+10μg/ml‐1 vancomycin (vanco group)
Study: 15383107
Drug: Diclofenac suppositories
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac suppositories (two x 100 mg)
Study: 15383107
Drug: Placebo suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppositories (Anusol)
Study: 11195739
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cefepime
Study: 11195739
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefepime
Study: 9703380
Drug: GHRH infusion
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH infusion (0.33 microg/kg every 90 min for 3 days)
Study: 2897978
Drug: Suriclone 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suriclone 0.4 mg
Study: 7927120
Drug: Suriclone 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suriclone 0.4 mg + Imipramine 75 mg
Study: 2789922
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 25 mg folinic acid
Study: 2789922
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 25 mg folinic acid
Study: 788759
Drug: Hydrallazine (75‐150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrallazine (75‐150 mg/day)
Study: 788759
Drug: Phentolamine (60‐120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine (60‐120 mg/day)
Study: 29351538
Drug: Cotrimoxazole 960
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotrimoxazole 960 mg tablets p.o. administered 14 and 2 hours before catheter removal
Study: 29351538
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics administered
Study: 19951427
Drug: Dimeticone 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimeticone 4% lotion
Study: 7506145
Drug: Naproxen (500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500mg twice daily)
Study: 27565018
Drug: Dual antithrombotic
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antithrombotic therapy with dabigatran etexilate (110 or 150 mg twice daily) and a P2Y12 inhibitor (either clopidogrel or ticagrelor)
Study: 27565018
Drug: Triple antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antithrombotic therapy with warfarin, a P2Y12 inhibitor (either clopidogrel or ticagrelor), and low-dose aspirin (for 1 or 3 months, depending on stent type)
Study: 25000528
Drug: Palmitate treatment
Normalized name: palmitate
DrugBank: Palmitic Acid (DB03796)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmitate treatment (300 µM) for three days
Study: 25000528
Drug: Palmitate treatment
Normalized name: palmitate
DrugBank: Palmitic Acid (DB03796)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmitate treatment (300 µM) for one day
Study: 10809860
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied NG-monomethyl-L-arginine (L-NMMA) in aqueous cream BP
Study: 10809860
Drug: Aqueous cream
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous cream BP alone (control)
Study: 8752293
Drug: Quadrivalent rhesus
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent rhesus rotavirus-based human rotavirus vaccine
Study: 29565762
Drug: Ergocalciferol 50,000
Normalized name: ergocalciferol 50,000 intl units oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergocalciferol 50,000 IU (treatment)
Study: 29565762
Drug: Crossover from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover from control to treatment group (for months 6-10)
Study: 26462724
Drug: G-CSF (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (6 mg administered subcutaneously every 2 weeks for 12 weeks)
Study: 22587573
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac 0.5% drops
Study: 19799615
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) for 29 days
Study: 17566099
Drug: l-arginine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine with ghrelin
Study: 17566099
Drug: l-arginine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine with CRH
Study: 17566099
Drug: ghrelin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ghrelin and CRH with l-arginine
Study: 11257751
Drug: Local corticosteroid
Normalized name: Corticosteroids acting locally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local corticosteroid injections
Study: 6152880
Drug: Beta-receptor blockade
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-receptor blockade continued until surgery (n = 48)
Study: 6152880
Drug: Beta-receptor blockade
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-receptor blockade gradually withdrawn (n = 51)
Study: 30835307
Drug: Placebo without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo without therapy (n=257)
Study: 30835307
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with therapy (n=256)
Study: 30835307
Drug: Supplements without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplements without therapy (n=256)
Study: 30835307
Drug: Supplements with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplements with therapy (n=256)
Study: 29039320
Drug: Ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 100 mg fast dispersible tablets (test)
Study: 21561896
Drug: GLP‐1 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP‐1 infusion at 1.2 pmol/kg/min starting 30 min before dobutamine stress echocardiography (DSE)
Study: 21561896
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no GLP‐1 infusion)
Study: 17475965
Drug: (18)F‐FDG PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: (18)F‐FDG PET/CT with delayed images after furosemide and oral hydration
Study: 25992523
Drug: Bromazepam (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam (6 mg)
Study: 1579628
Drug: Bromazepam (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam (12 mg)
Study: 1579628
Drug: Bromazepam (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam (6 mg and 12 mg)
Study: 4040550
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin (120 mg/m2)
Study: 4040550
Drug: Low-dose cisplatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cisplatin (60 mg/m2)
Study: 31319633
Drug: MCT in
Normalized name: MCT
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT in liquid form (MCT-L)
Study: 31319633
Drug: LCT in
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCT in liquid form (Con-L)
Study: 11826229
Drug: Xylitol lozenges
Normalized name: xylitol Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol lozenges
Study: 15932659
Drug: Spironolactone 40
Normalized name: spironolactone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 40 mg/d
Study: 12460700
Drug: CC genotype
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC genotype in white participants with treated hypertension
Study: 12460700
Drug: CC genotype
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC genotype in white participants
Study: 10342710
Drug: DHEA 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 200 mg/d
Study: 29926711
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg HBV vaccine
Study: 29926711
Drug: 40 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 μg HBV vaccine
Study: 26542491
Drug: liraglutide (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide (1.8 mg before intervention, followed by 0.6 mg for 2 days, 1.2 mg for 2 days, and 1.8 mg for 3 days)
Study: 17690713
Drug: Advances in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advances in antigen-specific therapies
Study: 8519716
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac (group 2)
Study: 2191712
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (400 mg)
Study: 2191712
Drug: Acyclovir ophthalmic
Normalized name: acyclovir Ophthalmic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir ophthalmic ointment (3%)
Study: 31775064
Drug: Daily assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily assessment schedule
Study: 31775064
Drug: Weekly assessment
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly assessment schedule
Study: 31420412
Drug: Primary cytoreductive
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary cytoreductive surgery followed by 6 cycles of platinum-based chemotherapy
Study: 31420412
Drug: Interval cytoreductive
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval cytoreductive surgery following 3 cycles of neoadjuvant chemotherapy and then 3 cycles of platinum-based chemotherapy
Study: 23334782
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg po one hour before surgery
Study: 16508700
Drug: 1,200 mg
Normalized name: lecithin 1,200 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg calcium plus 800 IU cholecalciferol (n=33)
Study: 16508700
Drug: 1,200 mg
Normalized name: lecithin 1,200 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg calcium (n=31)
Study: 11775134
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg eprosartan
Study: 11775134
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg eprosartan
Study: 8276044
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) at 0.02 microgram.kg‐1.min‐1 infusion during bypass
Study: 11876707
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg/day) and lansoprazole (30 mg/day)
Study: 11876707
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg/day), lansoprazole (30 mg/day), and clarithromycin (500 mg b.d.)
Study: 29306453
Drug: Caffeine containing
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine containing weight loss supplement
Study: 27389521
Drug: Nine further
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nine further sessions of integrated treatment
Study: 27389521
Drug: Nine further
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nine further sessions of alcohol-focused treatment
Study: 27389521
Drug: Nine further
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nine further sessions of depression-focused treatment
Study: 27389521
Drug: Integrated interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated interventions (incorporating motivational interviewing and cognitive behaviour therapy)
Study: 22795645
Drug: Oxytocin administration
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin administration to father
Study: 22795645
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration to father
Study: 20082715
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of melatonin and omeprazole
Study: 12207630
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (200 ml)
Study: 12207630
Drug: Tap water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tap water (200 ml)
Study: 10792845
Drug: G-CSF (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (0.3 mg/ml, 3 times a week for 12 weeks)
Study: 8777829
Drug: CO2-enriched (5%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2-enriched (5%) gas mixture with low-dose scopolamine (scopoderm TTS)
Study: 8777829
Drug: Voluntary hyperventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voluntary hyperventilation with low-dose scopolamine (scopoderm TTS)
Study: 6097665
Drug: Enalapril maleate
Normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril maleate (40 mg) in fasting state
Study: 6097665
Drug: Enalapril maleate
Normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril maleate (40 mg) with a standard breakfast
Study: 20932583
Drug: Baerveldt glaucoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baerveldt glaucoma implant (BGI)
Study: 29908803
Drug: Fixed milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed milk allowance (FIX) of 6 to 8 L/d from day 1 after birth
Study: 29908803
Drug: Slowly increasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slowly increasing milk allowance (INC) starting from 4 to 5 L/d to reach 6 to 8 L/d over 7 to 14 days
Study: 22652379
Drug: Tomato paste
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato paste supplementation (70 g containing 33.3 mg of lycopene)
Study: 16115357
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg elemental Cu/d as CuSO4
Study: 16115357
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg elemental Cu/d as CuSO4
Study: 16115357
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg elemental Cu/d (control)
Study: 1722167
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 alpha-reductase inhibitor); varying doses administered to men with benign prostatic hyperplasia.
Study: 28925286
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage VFE (four times)
Study: 28925286
Drug: Traditional dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional dosage VFE (twice)
Study: 28925286
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage VFE (once)
Study: 23828145
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (45 mg/day) and risedronate (2.5 mg/day or 17.5 mg/week)
Study: 23828145
Drug: Risedronate alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate alone (2.5 mg/day or 17.5 mg/week)
Study: 15208869
Drug: DMEM-therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMEM-therapy
Study: 3307061
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of azathioprine, cyclosporine, and prednisone (+/- ALG)
Study: 30489432
Drug: High-dose calfactant
Normalized name: Calfactant
DrugBank: Calfactant (DB06415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose calfactant (8.0 mg/ml)
Study: 30489432
Drug: Low-dose calfactant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose calfactant (0.8 mg/ml)
Study: 29523450
Drug: Additional early
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional early dose of measles vaccine (MV) 4 weeks after the third dose of DTP-containing Pentavalent vaccine and standard MV at 9 months
Study: 29523450
Drug: Standard measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard measles vaccine (MV) at 9 months (control)
Study: 29523450
Drug: Additional early
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional early dose of measles vaccine (MV) in children not exposed to an OPV campaign after enrolment
Study: 24683472
Drug: Elevated plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated plasma levels of IL‐2 receptor alpha (IL‐2 RA)
Study: 24683472
Drug: Elevated plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated plasma levels of tumour necrosis factor receptor type I
Study: 22078632
Drug: 30 mcg
Normalized name: Avonex 30 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mcg ethinyl estradiol (EE)/150 mcg levonorgestrel (LNG)
Study: 22078632
Drug: 20 mcg
Normalized name: Caverject 20 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mcg EE/100 mcg LNG
Study: 22078632
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose pill (30 mcg EE/150 mcg LNG)
Study: 22078632
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose pill (20 mcg EE/100 mcg LNG)
Study: 19293263
Drug: dDAVP administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: dDAVP administration
Study: 17712402
Drug: Intradermal LIPO-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal LIPO-4 vaccine (0.1 ml, 100 microg of each peptide)
Study: 17712402
Drug: Intramuscular LIPO-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular LIPO-4 vaccine (0.5 ml, 500 microg of each peptide)
Study: 11125269
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% indomethacin solution
Study: 15256991
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% fluorometholon acetate